STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Krystal Biotech (NASDAQ: KRYS), a commercial-stage biotechnology company, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 6, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 am ET on the same day to discuss the results and provide a business update.

Investors and the public can access the live webcast through a dedicated link, and a replay will remain available for at least 30 days on the company's investor relations website.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

+2.35% News Effect

On the day this news was published, KRYS gained 2.35%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

PITTSBURGH, April 17, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 6, 2025, prior to the open of U.S. markets.

The Company’s management will also host a conference call and webcast at 8:30 am ET on Tuesday, May 6, 2025, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: https://www.webcaster4.com/Webcast/Page/3018/52291.

For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at www.krystalbio.com.

About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

CONTACT
Investors and Media:
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com            


FAQ

When will Krystal Biotech (KRYS) release Q1 2025 earnings?

Krystal Biotech will release Q1 2025 earnings on Tuesday, May 6, 2025, before U.S. markets open.

How can investors access Krystal Biotech's Q1 2025 earnings call?

Investors can access the live webcast at 8:30 am ET on May 6, 2025, through the company's provided webcast link or investor relations website.

Will there be a replay available for Krystal Biotech's Q1 2025 earnings call?

Yes, a replay will be available for at least 30 days on the Investors section of Krystal Biotech's website at www.krystalbio.com.

What time is Krystal Biotech's Q1 2025 earnings conference call?

The earnings conference call and webcast is scheduled for 8:30 am ET on Tuesday, May 6, 2025.
Krystal Biotech

NASDAQ:KRYS

KRYS Rankings

KRYS Latest News

KRYS Latest SEC Filings

KRYS Stock Data

7.16B
24.79M
11.86%
100.94%
11.91%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
PITTSBURGH